Pyxis Oncology Inc
NASDAQ:PYXS

Watchlist Manager
Pyxis Oncology Inc Logo
Pyxis Oncology Inc
NASDAQ:PYXS
Watchlist
Price: 1.65 USD -2.37% Market Closed
Market Cap: 98.1m USD
Have any thoughts about
Pyxis Oncology Inc?
Write Note

Pyxis Oncology Inc
Net Issuance of Common Stock

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Pyxis Oncology Inc
Net Issuance of Common Stock Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Issuance of Common Stock CAGR 3Y CAGR 5Y CAGR 10Y
Pyxis Oncology Inc
NASDAQ:PYXS
Net Issuance of Common Stock
$6.2m
CAGR 3-Years
438%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Net Issuance of Common Stock
-$1.1B
CAGR 3-Years
-10%
CAGR 5-Years
16%
CAGR 10-Years
-15%
Gilead Sciences Inc
NASDAQ:GILD
Net Issuance of Common Stock
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Net Issuance of Common Stock
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Net Issuance of Common Stock
-$782m
CAGR 3-Years
11%
CAGR 5-Years
-48%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Net Issuance of Common Stock
-$243.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Pyxis Oncology Inc
Glance View

Market Cap
98.1m USD
Industry
Biotechnology

Pyxis Oncology, Inc. engages in the development of antibody therapeutics. The company is headquartered in Cambridge, Massachusetts and currently employs 56 full-time employees. The company went IPO on 2021-10-08. The firm has developed a portfolio of antibody drug conjugate (ADC), immuno-oncology (IO), product candidates, and monoclonal antibody (mAb), preclinical discovery programs that are developing as monotherapies and in combination with other therapies. Its pipeline includes PYX-106, PYX-102, PYX-201, PYX-202 and PYX-203. Its PYX-106 is an investigational, fully human IgG1 isotype Siglec-15 targeting antibody that is designed to block Siglec-15-mediated suppression of T-cell proliferation and function. PYX-102 is an investigational immune-therapeutic consisting of a ligand-blocking antibody which rescues KLRG1-mediated suppression of human CD8+ T cells. PYX-201 is an investigational ADC consisting of an immunoglobulin G1 (IgG1), anti-fibronectin Extradomain-B (EDB), mAb site-specifically conjugated to auristatin via a cathepsin B-cleavable linker.

PYXS Intrinsic Value
1.03 USD
Overvaluation 38%
Intrinsic Value
Price

See Also

What is Pyxis Oncology Inc's Net Issuance of Common Stock?
Net Issuance of Common Stock
6.2m USD

Based on the financial report for Dec 31, 2023, Pyxis Oncology Inc's Net Issuance of Common Stock amounts to 6.2m USD.

What is Pyxis Oncology Inc's Net Issuance of Common Stock growth rate?
Net Issuance of Common Stock CAGR 3Y
438%

Over the last year, the Net Issuance of Common Stock growth was 3 368%. The average annual Net Issuance of Common Stock growth rates for Pyxis Oncology Inc have been 438% over the past three years .

Back to Top